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Precis: The removal and evaluation of 18 or more lymph nodes was associated with improved 
overall survival in node-positive mucosal head and neck cancer.  This threshold should be further 
evaluated as a potential measure of quality in neck dissections. 
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Abstract 
Background: Prospective quality metrics for neck dissection have not been established for 
patients with head and neck squamous cell carcinoma. The purpose of this study is to investigate 
the association between lymph node counts from neck dissection, local-regional recurrence, and 
overall survival. 
Methods: The number of lymph nodes counted from neck dissection in patients treated on NRG 
Oncology RTOG trials 9501 and 0234 was evaluated for its prognostic impact on overall 
survival using a multivariate Cox model adjusted for demographic, tumor, and lymph node data, 
and stratified by postoperative treatment group. 
Results: 572 patients were analyzed at median follow-up of eight years. 98% of patients were 
pathologically N+. Median number of lymph nodes recorded on the left and right sides were 24 
and 25. Fewer than 18 nodes identified was associated with worse overall survival relative to ≥18 
nodes (hazard ratio 1.38, 95%CI 1.09-1.74, p=0.007). The difference appeared to be driven by 
local-regional failure (HR 1.46, 95%CI 1.02-2.08, p=0.04) but not distant metastases (HR 1.08, 
95%CI 0.77-1.53, p=0.65).  When analysis was limited to NRG Oncology RTOG 0234 patients, 
adding p16 status to the model did not affect the hazard ratio for dissected nodes and the effect of 
nodes was not different by p16 status. 
Conclusion: The removal and identification of 18 or more lymph nodes was associated with 
improved overall survival and lower rates of local-regional failure, and should be further 
evaluated as a measure of quality in neck dissections for mucosal squamous cell carcinoma. 
Keywords: Quality indicators, head and neck cancer, neck dissection, survival, surgery 
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Introduction 
Neck dissection is the cornerstone of modern head and neck surgery. After Crile proposed the 
systematic management of regional lymphatics of the neck in 1906,
1
 the procedure became 
widely practiced and adopted as an integral aspect of managing head and neck cancer. Beginning 
in 1951, Hayes Martin promoted the “radical” neck dissection as an en-bloc ipsilateral resection 
of all lymphatic tissues of the neck as well as the sternocleidomastoid muscle (SCM), internal 
jugular (IJ) vein, and the spinal accessory nerve (CN XI).
2
 But over time, the neck dissection 
evolved. In 1984, Byers introduced the more conservative modified radical neck dissection
3 
that 
preserved the SCM, IJ and CN XI, and eventually advocated for the selective neck dissection
 
that 
removed fewer than all five levels of the neck.
4
 
Despite efforts to standardize and classify technique,
5
 the practice of neck dissection now 
varies widely across centers and from surgeon to surgeon. As such, there may be significant 
variability in quality of cervical lymphadenectomy. For other solid malignancies, such as 
colorectal cancer, prospective studies have demonstrated the impact of the quality and extent of 
surgery on survival, and, in particular, the number of lymph nodes retrieved during regional 
nodal dissection. For patients with Stage II and III colorectal cancer, removing 12 lymph nodes 
or more is associated with increased overall survival.
6-9
 This quality metric was adopted for 




In the head and neck surgical oncology literature, retrospective single and multi-center 
studies have attempted to address surgical quality in neck dissection. 
11,12
 However, to our 
knowledge, no prospective data has been examined to determine relationships between the 
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number of nodes removed in neck dissection and oncologic outcomes such as locoregional 
recurrence or survival. 
Here we investigate whether or not the number of lymph nodes reported following a neck 
dissection for node-positive mucosal squamous cell carcinoma correlates to overall survival in 
prospective NRG Oncology RTOG clinical trials. Our hypothesis is that higher lymph node 
counts for neck dissections is correlated with improved survival. We aim to identify a cut-point 
that would be a proxy for quality when measuring lymph nodes retrieved during neck dissection. 
Methods 
This study included patients treated on postoperative trials NRG Oncology RTOG 9501
13
and 
NRG Oncology RTOG 0234.
14
 NRG Oncology RTOG 9501 was a phase III trial comparing 
radiation alone to radiation with concurrent cisplatin. NRG Oncology RTOG 0234 was a 
randomized phase II trial comparing two experimental regimens (1) radiation with concurrent 
cisplatin and cetuximab and (2) radiation with concurrent docetaxel and cetuximab to historical 
control NRG Oncology RTOG 9501 chemoradiation arm. Protocol approval was received from 
the Institutional Review Board at each study site and informed consent was obtained from each 
patient prior to participation. 
The analysis was limited to patients with complete data for the following potential 
covariates: age, gender, race, Zubrod performance status, smoking history, primary site, 
pathologic T stage, pathologic N stage, type of neck dissection (unilateral or bilateral), 
extracapsular nodal extension, positive margin, number of lymph nodes counted, and number of 
positive lymph nodes. For patients with bilateral neck dissection, the mean of the two sides was 
used for the number of counted lymph nodes. Possible differences in distributions of patient 
characteristics were tested as follows: continuous or ordinal variable, Wilcoxon rank-sum test; 
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categorical variable (for two groups and two levels), Fisher’s exact test; other categorical 
variable, Pearson chi-square test. 
The number of lymph nodes counted from neck dissection was evaluated for its 
prognostic impact on overall survival, local-regional failure, and distant metastasis using a 
multivariate Cox model adjusted for demographic, tumor, and lymph node data, and stratified by 
postoperative treatment group. Overall survival was defined as the time from randomization to 
death (event) or last follow-up. Rates were estimated by the Kaplan-Meier method.
15
 Local-
regional failure is defined as the time from randomization to local or regional relapse (event), 
death (competing risk), or last follow-up. Distant metastasis is defined as the time from 
randomization to distant metastasis (event), death (competing risk), or last follow-up. Rates were 
estimated by the cumulative incidence method.
16




All analyses that included both trials were stratified by treatment group: (1) NRG 
Oncology RTOG 9501 radiation; (2) NRG Oncology RTOG 9501 chemoradiation; (3) NRG 
Oncology RTOG 0234 chemoradiation and cetuximab. Models were compared by Akaike 
information criterion (AIC). The initial model with all covariates was reduced by minimizing 
AIC. Then number of lymph nodes dissected was added as a categorical variable. An initial 
cutpoint of 18 lymph nodes was used based on previously published analyses in node negative 
patients.
11  
The following sensitivity analyses were performed: [1] limiting to unilateral neck 
dissections; [2] censoring patients at five years; [3] in NRG Oncology RTOG 9501, adding 
assigned treatment (chemoradiation vs. radiation) to the model; [4] in NRG Oncology RTOG 
0234, adding p16 status (p16-negative vs. p16-positive) to the model. 
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Results 
Patient Demographics and Tumor Characteristics 
Six-hundred ninety-seven patients were enrolled to NRG Oncology RTOG 9501 (n=459) or 
NRG Oncology RTOG 0234 (n=238) of whom 613 (NRG Oncology RTOG 9501: 410; NRG 
Oncology RTOG 0234: 203) were eligible and included in analysis of protocol endpoints. Of 
these, 572 (93.3%) were included in this secondary analysis (Figure 1). Median follow-up for 
surviving patients was 8.0 years (range 0.2 to 14.0). 
Patient and tumor characteristics by number of lymph nodes dissected (< 18 and ≥ 18) are 
shown in Table 1. Overall 35% percent had a bilateral neck dissection. The median number of 
positive lymph nodes was three. The median number of counted lymph nodes on the left and 
right sides were 24 and 25, respectively. 98% of patients were N+. Prospective data collection 
for RTOG 9501 and 0234 did not include notation about the level of each harvested node and 
which lymph node levels were dissected. Distributions of N stage (p<0.001), type of neck 
dissection (p<0.001), lymph node density (p<0.001), and margin status (p=0.05) differ 
significantly between the two groups. The distribution of counted lymph nodes is shown in 
Figure 2 and shows a very similar shape as the SEER data from Agrama.
18
 The median lymph 
node density (positive nodes/total nodes) between the two groups was 0.23 (<18) verses 0.09 
(≥18) (p<0.001). 
In 130 patients on NRG Oncology RTOG 0234 for whom p16 status was known, 57 were 
p16-positive (43.8%). Distributions of primary site (p<0.001), T stage (p<0.001), and margin 
status (p<0.001) differ between the p16-positive and p16-negative groups. Median number of 
resected nodes was 27 for the p16-positive group and 23 for the p16-negative group (p=0.14).  
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The median lymph node density (positive nodes/total nodes) between the two groups was 0.12 
(p16-positive) verses 0.11 (p16-negative) (p=0.70.). 
Cut point Threshold 
Table 2 shows the full and reduced models (minimum AIC) for overall survival prior to adding 
counted lymph nodes.  The reduced model was created by removing variables that did not 
contribute to better model fit (AIC) to achieve a more parsimonious model.  In the third model, 
counted lymph nodes were added using a single cut point threshold to differentiate two separate 
groups of patients. Having < 18 counted lymph nodes significantly associated with worse overall 
survival [hazard ratio 1.38, 95% confidence interval (CI) 1.09 to 1.74, p=0.007] after adjustment 
for age, race, Zubrod, smoking history, primary site, pathologic T stage, ECE, and number of 
positive nodes. Including the additional variables that were left out of our final model (gender, N 
stage, unilateral/bilateral, margin status) does not change the results appreciably [hazard ratio 
1.37, 95% confidence interval 1.08 to 1.74, p=0.009]. Figure 3 demonstrates overall survival 
curves for < 18 vs. ≥ 18 lymph nodes. The model using 18 lymph nodes as a cut point has 
maximum effect size (largest hazard ratio) and minimum AIC among all possible models with a 






Sensitivity analyses were performed for the effect of < 18 vs. ≥ 18 counted nodes on overall 
survival. Limited to patients with unilateral neck dissection, the hazard ratio is 1.43 (95% CI 
1.05 to 1.95). Censoring all patients at five years yields a hazard ratio of 1.30 (95% CI 1.01 to 
1.68). Limited to NRG Oncology RTOG 9501, adding assigned treatment (chemoradiation vs. 
radiation) to the model does not change the hazard ratio for counted nodes: 1.29 (95% CI 0.99-
1.69) with treatment in the model, 1.28 (95% CI 0.98-1.67) without. Including an interaction 
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term in the NRG Oncology RTOG 9501 model (assigned treatment X counted nodes) yields an 
interaction p-value of 0.27, so it does not appear that the effect of counted nodes differs by 
treatment. Limited to patients in NRG Oncology RTOG 0234 with known p16 status, adding p16 
to the model does not affect the hazard ratio for counted nodes: 1.51 (95% CI 0.87-2.63) with 
p16 in the model, 1.54 (95% CI 0.88-2.67) without. Including an interaction term in the NRG 
Oncology RTOG 0234 model (p16 status X counted nodes) yields an interaction p-value of 0.99, 
so it does not appear that the effect of counted nodes differs by p16 status. 
Patterns of Failure 
Patterns of failure are shown in Figures 4 and 5. Patients with < 18 nodes had significantly more 
local-regional failure (hazard ratio 1.46, 95% confidence interval 1.02 to 2.08, p=0.04; Figure 4) 
but not distant metastasis (hazard ratio 1.08, 95% confidence interval 0.77 to 1.53, p=0.65; 
Figure 5). 
Discussion 
Using data from prospective clinical trials, we found that lymph node counts ≥ 18 in patients 
with node-positive mucosal squamous cell carcinoma are associated with improved survival and 
decreased rates of local-regional recurrence. The effect is similar for p16-positive and p16-
negative patients. To our knowledge, this study is the first to show this effect in node-positive 
patients with head and neck cancer, and offers a potential quality metric for neck dissection. 
Furthermore, to our knowledge, this study is the first to query prospective data to identify 
a correlation between lymph node counts and oncologic outcomes. Several teams have 
previously investigated this potential relationship using single or multi-institutional retrospective 
data sets. Gil et al used a cut point of 30 lymph nodes, Ryu et al used a cut point of 52 lymph 
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nodes, and Shrime et al used lymph node count as a continuous variable.
19-21
 These values were 
considerably higher than our cut point which is possibly why they did not demonstrate a survival 
difference. Patel el al evaluated the impact of lymph node density, not counts, on overall survival 
on over 4200 patients.  As part of their secondary analysis, a single cut point of 20 was tested but  
did not demonstrate significance, though it is unclear if other cut points would have shown a 
difference in survival.
22
 Ebrahimi and colleagues studied 225 patients with N0 SCC of the oral 
cavity from the Sydney Head and Neck Institute, finding that patients with lymph node counts < 
18 had an increased risk of mortality (HR 2.0; 95% CI, 1.1-3.6; P=0.020).
11 
 A pooled multi-
institutional retrospective review of 1,567 N0 SCC oral cancer patients from nine cancer centers 
found that a nodal yield < 18 was associated with decreased overall survival (HR 1.69; 95% CI 
1.22–2.34; p = 0.002) and increased risk of locoregional recurrence (HR 1.53; 95% CI 1.04–
2.26; p = 0.032).
12
 It also supports the theory that more thorough neck dissections removing 
greater than 18 nodes may improve outcomes. 
The use of lymph node counts fits in with a larger national trend towards using specific 
numbers to address the quality of care. Recent efforts have shown that for clinicians to begin to 
improve cancer care, multidisciplinary teams must first have a way to measure quality. However, 
devising measurement tools can be challenging and frequently controversial. In order to do so, 
the complexity of medical care, patient presentations (natural history and variability of disease), 
and tumor heterogeneity must be distilled into a clinically robust metric that is easily compared 
across physicians and institutions. These metrics will always have exceptions, however when 
multiple metrics are used to evaluate the care of a larger group of patients, a clearer picture of 
quality should emerge. These metrics should ideally represent intermediate points of care that 
can be directly affected by providers to improve long-term outcomes. Lymph node counts from 
Page 12 of 26Cancer










Neck dissection lymph node count and survival 
12 
neck dissection is one such potential metric and based on the findings in this study, may deserve 
further evaluation. 
Given the additional factors that might impact the nodal count, it is possible that this 
metric may only be able to be reached in a significant number of, but not all, patients even in an 
optimal setting.  In this case, implementation would have to be considered at a hospital level or a 
surgeon level across many cases, as opposed to at the individual patient level. Further studies of 
the impact of such a metric used in this fashion need to be first evaluated before any 
recommendation could be made. 
The relationship of lymph node counts and survival is an association but may not 
necessarily equate with causality. There are multiple aspects of patient care that may be the 
ultimate cause of the improved survival in patients with higher node counts. Lymph node counts 
are dependent on the technique of both the surgeon and pathologist. While the technical skill of a 
surgeon may remove more lymphatic tissue, ultimately the pathologist is responsible for 
identifying and evaluating the lymph nodes. Differences in the numbers of lymph nodes retrieved 
in the pathology laboratory from a neck dissection may vary due to several factors. Surgeons 
with less experience may have more difficulty in identifying lymph nodes as compared to those 
with more experience.
23
 Degree of tissue fixation can result in different lymph node yields. 
Longer duration of formalin fixation has been shown to yield increased lymph node counts.
24
 
Prior radiation therapy to the neck has also been shown to result in decreased lymph node yield 
from lymph node dissections.
25
 
Higher lymph node counts in patients cannot be separated from the structural and process 
related aspects of a patient’s care. Patients who have higher lymph node counts may be cared for 
in higher volume institutions, have better perioperative care, be treated by more experienced 
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radiation oncologists and medical oncologists, or be treated at more integrated academic medical 
centers. While we have likely minimized some of these effects given the greater consistency of 
patients entered into prospective clinical trials (NRG Oncology RTOG 9501 and NRG Oncology 
RTOG 0234) we cannot totally eliminate any potential influence of the type of institution or 
experience of the treating physicians. A study by Wuthrick et al. looked at patients treated at 
high-accruing versus low-accruing centers based on accrual to 21 RTOG HNC trials.
26
 Patients 
at high-accruing centers had fewer protocol deviations (6% v 18%; P < .001) and better overall 
survival (69.1% v 51.0%; P = .002). Therefore, while lymph node counts are associated with 
improved survival, we cannot determine what component of that is from direct removal of cancer 
cells within the regional lymphatics and other factors that might positively correlate with higher 
lymph node counts. 
Finally, this report is a post-hoc study of prospectively collected data from clinical trials 
designed to evaluate adjuvant therapy in node-positive patients. We were unable to control for 
system level factors and unmeasured process measures that may have influenced outcomes.
26
 
Further studies should be performed on larger datasets with standardized treatment protocols to 
better isolate the effect of lymph node count on survival. 
Neck dissections with 18 or greater lymph nodes are associated with improved survival 
and lower rates of local-regional failure in node-positive patients. Based on the current literature 
and this secondary analysis from prospective clinical trials, lymph node counts should be further 
evaluated as a potential measure of quality in head and neck surgery. 
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Figure Legends 
Figure 1. CONSORT diagram 
Figure 2. Distribution of Number of Counted Lymph Nodes (mean) 
Figure 3. Kaplan-Meier estimates of overall survival by the number of counted nodes (n=572; 
352 events). Patients with < 18 counted lymph nodes have worse survival compared to those 
with ≥ 18 nodes (univariate hazard ratio stratified by treatment group 1.40, 95% confidence 
interval 1.11 to 1.76, p=0.005) with five-year survival rates of 42.1% (95% confidence interval 
34.3 to 49.9) and 51.3% (95% confidence interval 46.4 to 56.2). 
Figure 4. Cumulative incidence of local-regional failure by the number of sampled nodes 
(n=572; 141 events). Patients with < 18 sampled lymph nodes have more local-regional failure 
compared to those with ≥ 18 nodes (univariate hazard ratio stratified by treatment group 1.46, 
95% confidence interval 1.02 to 2.08, p=0.04) with 5-year local-regional failure rates of 27.7% 
(95% confidence interval 20.9 to 34.8) and 22.1% (95% confidence interval 18.4 to 26.5). 
Figure 5. Cumulative incidence of distant metastasis by the number of sampled nodes (n=572; 
167 events). Patients with < 18 sampled lymph nodes have similar rates of distant metastasis 
compared to those with ≥ 18 nodes (univariate hazard ratio stratified by treatment group 1.08, 
95% confidence interval 0.77 to 1.53, p=0.65) with 5-year distant metastasis rates of 27.2% 
(95% confidence interval 20.5 to 34.3) and 28.7% (95% confidence interval 24.4 to 33.2). 
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Table 1. Patient and Tumor Characteristics by Number of Resected Nodes (mean) 
 
< 18  
(n=162)                     
≥ 18 
(n=410)                     
Total 
(n=572)                    
 
Treatment group, p=0.25 [1]    
RT   47  (  29.0%) 149  (  36.3%) 196  (  34.3%) 
RT+CT   59  (  36.4%) 135  (  32.9%) 194  (  33.9%) 
RT+CT+cetuximab   56  (  34.6%) 126  (  30.7%) 182  (  31.8%) 
 
Age (years), p=0.26 [2]    
Mean (standard deviation) 56.4 (9.43) 55.6 (9.58) 55.8 (9.53) 
Median (min-max) 58 (27-79) 55 (21-80) 56 (21-80) 
 
Gender, p=1.00 [3]    
Male 134  (  82.7%) 339  (  82.7%) 473  (  82.7%) 
Female   28  (  17.3%)   71  (  17.3%)   99  (  17.3%) 
 
Race, p=0.72 [3]    
White 129  (  79.6%) 333  (  81.2%) 462  (  80.8%) 
Non-white   33  (  20.4%)   77  (  18.8%) 110  (  19.2%) 
 
Zubrod performance status, 
p=0.30 [3] 
   
0 84 (51.9%) 233 (56.8%) 317 (55.4%) 
1 76 (46.9%) 173 (42.2%) 249 (43.5%) 
2 2 (1.2%) 4 (1.0%) 6 (1.0%) 
 
Smoking history, p=0.50 [1]    
Never 21 (13.0%) 67 (16.3%) 88 (15.4%) 
Former 81 (50.0%) 187 (45.6%) 268 (46.9%) 
Current 60 (37.0%) 156 (38.0%) 216 (37.8%) 
 
Primary site, p=0.16 [1]    
Oral Cavity   56  (  34.6%) 137  (  33.4%) 193  (  33.7%) 
Oropharynx   56  (  34.6%) 173  (  42.2%) 229  (  40.0%) 
Hypopharynx   20  (  12.3%)   30  (    7.3%)   50  (    8.7%) 
Larynx   30  (  18.5%)   70  (  17.1%) 100  (  17.5%) 
 
T stage (surgical-pathological), 
p=0.88 [2] 
   
T1 30 (18.5%) 55 (13.4%) 85 (14.9%) 
T2 36 (22.2%) 125 (30.5%) 161 (28.1%) 
T3 42 (25.9%) 92 (22.4%) 134 (23.4%) 
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< 18  
(n=162)                     
≥ 18 
(n=410)                     
Total 
(n=572)                    
T4 54 (33.3%) 138 (33.7%) 192 (33.6%) 
 
N stage (surgical-pathological), 
p<0.001 [2] 
   
N0     4  (    2.5%)     7  (    1.7%)   11  (    1.9%) 
N1     5  (    3.1%)   23  (    5.6%)   28  (    4.9%) 
N2a     8  (    4.9%)   26  (    6.3%)   34  (    5.9%) 
N2b   86  (  53.1%) 276  (  67.3%) 362  (  63.3%) 
N2c   57  (  35.2%)   68  (  16.6%) 125  (  21.9%) 
N3     2  (    1.2%)   10  (    2.4%)   12  (    2.1%) 
 
AJCC stage (surgical-
pathological), p=0.98 [2] 
   
I     0  (    0.0%)     1  (    0.2%)     1  (    0.2%) 
III     6  (    3.7%)   14  (    3.4%)   20  (    3.5%) 
IV 156  (  96.3%) 395  (  96.3%) 551  (  96.3%) 
 
Type of neck dissection, 
p<0.001 [3] 
   
Unilateral   88  (  54.3%) 284  (  69.3%) 372  (  65.0%) 
Bilateral   74  (  45.7%) 126  (  30.7%) 200  (  35.0%) 
 
Counted lymph nodes (left) (n=116) (n=254) (n=370) 
Mean (standard deviation) 11.9 (6.10) 32.8 (14.38) 26.3 (15.76) 
Median (min-max) 12 (1-32) 31 (1-89) 24 (1-89) 
 
Counted lymph nodes (right) (n=120) (n=282) (n=402) 
Mean (standard deviation) 11.6 (5.74) 32.7 (13.50) 26.4 (15.20) 
Median (min-max) 11 (2-32) 31 (1-78) 25 (1-78) 
 
Counted lymph nodes (mean) 
[4] 
   
Mean (standard deviation) 11.7 (4.10) 34.1 (13.06) 27.7 (15.13) 
Median (min-max) 12 (2-17) 32 (18-89) 26 (2-89) 
 
Lymph nodes with 
pathologically confirmed 
metastasis (total), p=0.10 [2] 
   
Mean (standard deviation) 4.1 (3.23) 5.2 (5.13) 4.9 (4.69) 
Median (min-max) 3 (0-19) 3 (0-34) 3 (0-34) 
< 2   18  (  11.1%)   47  (  11.5%)   65  (  11.4%) 
>/= 2 144  (  88.9%) 363  (  88.5%) 507  (  88.6%) 
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< 18  
(n=162)                     
≥ 18 
(n=410)                     
Total 
(n=572)                    
 
Lymph node density 
(positive/counted), p<0.001 [2] 
   
Mean (standard deviation) 0.28 (0.21) 0.13 (0.13) 0.17 (0.17) 
Median (min-max) 0.23 (0.00-1.00) 0.09 (0.00-0.83) 0.12 (0.00-1.00) 
 
Extracapsular nodal extension, 
p=0.40 [3] 
   
No   76  (  46.9%) 176  (  42.9%) 252  (  44.1%) 
Yes   86  (  53.%) 234  (  57.1%) 320  (  55.9%) 
 
Positive margin, p=0.05 [3]    
No 122  (  75.3%) 339  (  82.7%) 461  (  80.6%) 
Yes   40  (  24.7%)   71  (  17.3%) 111  (  19.4%) 
 
 
[1] Pearson chi-square test. 
[2] Wilcoxon rank-sum test. 
[3] Fisher’s exact test. Zubrod 1 and 2 were combined. 
[4] If bilateral neck dissection mean of left and right sides; if unilateral, the number 
counted. 
Page 21 of 26 Cancer










Neck dissection lymph node count and survival 
21 








reduced model with 
counted nodes added 
Parameter                      HR (95%CI)                     
p-
value             HR (95%CI)                     p-value                     HR (95%CI)                     p-value                
 




0.05 1.24 (0.99-1.54) 0.06 
Gender (male vs. female) 1.20 (0.89-
1.63) 
0.24     




0.02 1.33 (1.03-1.72) 0.03 




<0.001 1.53 (1.23-1.90) <0.001 






0.007 1.34 (1.06-1.69) 0.01 






<0.001 1.69 (1.33-2.14) <0.001 




<0.001 2.22 (1.48-3.33) <0.001 
N stage (N2c-3 vs. N0-2b) 1.19 (0.88-
1.60) 
0.26     




0.34     




<0.001 1.77 (1.42-2.21) <0.001 
Positive margin (yes vs. no) 1.08 (0.80-
1.47) 
0.62     




0.007 1.68 (1.16-2.45) 0.007 
Counted nodes (<18 vs. 
>/=18) 
    1.38 (1.09-1.74) 0.007 
AIC 3197.221  3192.466  3187.367  
 
Cox models were stratified by treatment group (RT, RT+CT, RT+CT+cetuximab). 
RT: radiation therapy; CT: chemotherapy; HR: hazard ratio; CI: confidence interval; PS: performance s
tatus; 
ECE: extracapsular nodal extension; AIC: Akaike information criterion. 
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